{
    "relation": [
        [
            "",
            "Number of Participants [units: participants]",
            "Age, Customized [units: Participants]",
            "Younger than 65 years",
            "65 years and older to younger than 75 years",
            "75 years and older",
            "Gender [units: Participants]",
            "Female",
            "Male",
            "Ethnicity (NIH/OMB) [1] [units: Participants]",
            "Hispanic or Latino",
            "Not Hispanic or Latino",
            "Unknown or Not Reported",
            "Race/Ethnicity, Customized [units: Participants]",
            "White",
            "Black or African American",
            "Asian",
            "Other",
            "Body Mass Index [units: Participants]",
            "Less than 25 kg/m^2",
            "25 kg/m^2 and greater",
            "27 kg/m^2 and greater",
            "30 kg/m^2 and greater"
        ],
        [
            "Placebo",
            "311",
            "",
            "259",
            "46",
            "6",
            "",
            "140",
            "171",
            "",
            "81",
            "43",
            "187",
            "",
            "241",
            "14",
            "54",
            "2",
            "",
            "28",
            "283",
            "240",
            "152"
        ],
        [
            "Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8)",
            "166",
            "",
            "141",
            "25",
            "0",
            "",
            "76",
            "90",
            "",
            "28",
            "16",
            "122",
            "",
            "105",
            "11",
            "49",
            "1",
            "",
            "20",
            "146",
            "123",
            "79"
        ],
        [
            "Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8)",
            "165",
            "",
            "142",
            "21",
            "2",
            "",
            "76",
            "89",
            "",
            "23",
            "20",
            "122",
            "",
            "108",
            "8",
            "49",
            "0",
            "",
            "18",
            "147",
            "129",
            "84"
        ],
        [
            "Dapagliflozin, 10 mg",
            "302",
            "",
            "260",
            "42",
            "0",
            "",
            "123",
            "179",
            "",
            "87",
            "31",
            "184",
            "",
            "239",
            "12",
            "49",
            "2",
            "",
            "34",
            "268",
            "238",
            "173"
        ],
        [
            "Total",
            "944",
            "",
            "802",
            "134",
            "8",
            "",
            "415",
            "529",
            "",
            "219",
            "110",
            "615",
            "",
            "693",
            "45",
            "201",
            "5",
            "",
            "100",
            "844",
            "730",
            "488"
        ]
    ],
    "pageTitle": "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01137474?sect=Xa0156&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 9,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981969.11/warc/CC-MAIN-20150728002301-00232-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 850667044,
    "recordOffset": 850651106,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Day 1 to Week 12 (Double-blind Period) Participant Flow for 2 periods Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 10 mg, daily with a morning meal. Dapagliflozin, 10 mg Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 5 mg, daily with a morning meal. Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 2.5 mg, daily with a morning meal. Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8) Participants with type 2 diabetes and inadequate glycemic and hypertension control while taking an oral antidiabetic drug (OAD) with or without insulin and an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), received dapagliflozin-matching placebo daily with a morning meal. Placebo Description \u00a0",
    "textAfterTable": "Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. All randomized participants who received a least 1 dose of double-blind study medication Reporting Groups \u00a0 Description Placebo Participants with type 2 diabetes and inadequate glycemic control while taking an oral antidiabetic drug (OAD) with or without insulin and an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), received dapagliflozin-matching placebo daily with a morning meal. Dapagliflozin, 2.5 mg (Randomized Before Protocol Amendment 8) Participants with type 2 diabetes and inadequate glycemic control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 2.5 mg, daily with a morning meal. Dapagliflozin, 5 mg (Randomized Before Protocol Amendment 8) Participants with type 2 diabetes and inadequate glycemic control while taking an OAD with or without insulin and an ACE inhibitor or ARB, received dapagliflozin, 5 mg, daily with a morning meal.",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}